Related references
Note: Only part of the references are listed.Mechanisms and therapeutic strategies for non-T2 asthma
Eric Sze et al.
ALLERGY (2020)
Different endotypes and phenotypes drive the heterogeneity in severe asthma
P. Jane McDowell et al.
ALLERGY (2020)
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline
Fernando Holguin et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Trends and Disparities in Asthma Biologic Use in the United States
Jonathan W. Inselman et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)
Safety of Reslizumab in Uncontrolled Asthma with Eosinophilia: A Pooled Analysis from 6 Trials
J. Christian Virchow et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)
Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma
Jonathan Corren et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)
Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab
Luis A. Perez de Llano et al.
ALLERGY (2020)
Development and initial validation of the Asthma Severity Scoring System (ASSESS)
Anne M. Fitzpatrick et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Estimation of Health and Economic Benefits of Clinic Versus Home Administration of Omalizumab and Mepolizumab
Marcus Shaker et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)
Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation
Audrey Le Floc'h et al.
ALLERGY (2020)
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma
Ioana Agache et al.
ALLERGY (2020)
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma
Ioana Agache et al.
ALLERGY (2020)
The evolving algorithm of biological selection in severe asthma
Nikolaos G. Papadopoulos et al.
ALLERGY (2020)
Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge
Claus Bachert et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma
Grainne d'Ancona et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Evolution and function of interleukin-4 receptor signaling in adaptive immunity and neutrophils
Lukas E. M. Heeb et al.
GENES AND IMMUNITY (2020)
An expert consensus framework for asthma remission as a treatment goal
Andrew Menzies-Gow et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Targeted deletion of the TSLP receptor reveals cellular mechanisms that promote type 2 airway inflammation
Hiroki Kabata et al.
MUCOSAL IMMUNOLOGY (2020)
Pharmacology and Therapeutics of Bronchodilators Revisited
M. G. Matera et al.
PHARMACOLOGICAL REVIEWS (2020)
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma
Ioana Agache et al.
ALLERGY (2020)
Dupilumab: Basic aspects and applications to allergic diseases
Kazuto Matsunaga et al.
ALLERGOLOGY INTERNATIONAL (2020)
Microbial Regulation of Enteric Eosinophils and Its Impact on Tissue Remodeling and Th2 Immunity
Rodrigo Jimenez-Saiz et al.
FRONTIERS IN IMMUNOLOGY (2020)
Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life
Bruno Sposato et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2020)
The emerging roles of eosinophils in mucosal homeostasis
Kathleen Shah et al.
MUCOSAL IMMUNOLOGY (2020)
Research Priorities in Pediatric Asthma: Results of a Global Survey of Multiple Stakeholder Groups by the Pediatric Asthma in Real Life (PeARL) Think Tank
Alexander G. Mathioudakis et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)
Critical Points on the Use of Biologicals in Allergic Diseases and Asthma
Ioana Agache et al.
ALLERGY ASTHMA & IMMUNOLOGY RESEARCH (2020)
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
Mario Castro et al.
ERJ OPEN RESEARCH (2020)
Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with Severe Eosinophilic Asthma: Phase IIIb Randomized, Controlled Trial (SOLANA)
Reynold A. Panettieri et al.
JOURNAL OF ASTHMA AND ALLERGY (2020)
Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study
Thomas B. Casale et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)
Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy
Yu-Chen Huang et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2019)
Cost-effectiveness and comparative effectiveness of biologic therapy for asthma To biologic or not to biologic?
William C. Anderson et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2019)
Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma
Geoffrey Chupp et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2019)
Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases
Ioana Agache et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
The use of biologics for immune modulation in allergic disease
Willem van de Veen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Severe asthma in children-a review of definitions, epidemiology, and treatment options in 2019
Husam Ahmed et al.
PEDIATRIC PULMONOLOGY (2019)
The Burden of Severe Asthma in France: A Case-Control Study Using a Medical Claims Database
Arnaud Bourdin et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)
Toward clinically applicable biomarkers for asthma: An EAACI position paper
Zuzana Diamant et al.
ALLERGY (2019)
Prioritizing research challenges and funding for allergy and asthma and the need for translational research-The European Strategic Forum on Allergic Diseases
Ioana Agache et al.
ALLERGY (2019)
Severe asthma: Entering an era of new concepts and emerging therapies: Highlights of the 4th international severe asthma forum, Madrid, 2018
Sven F. Seys et al.
ALLERGY (2019)
EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma
Ioana Agache et al.
ALLERGY (2019)
EAACI position paper: Influence of dietary fatty acids on asthma, food allergy, and atopic dermatitis
Carina Venter et al.
ALLERGY (2019)
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
Kenneth R. Chapman et al.
ALLERGY (2019)
Disease burden in patients with asthma before initiating biologics: A retrospective cohort database study
Hector Ortega et al.
ALLERGY AND ASTHMA PROCEEDINGS (2019)
Severe asthma in children: therapeutic considerations
Louise Selby et al.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation
John Efthimiou et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma
Davila Gonzalez I et al.
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY (2019)
Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats
Marta Calbet et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study
Luis Perez de Llano et al.
RESPIRATORY MEDICINE (2019)
IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states
Giulia Pellizzari et al.
EBIOMEDICINE (2019)
Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation
Diego Bagnasco et al.
ALLERGY (2019)
Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling
Mark Zak et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility
Marc Humbert et al.
RESPIRATORY MEDICINE (2019)
Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States
Russell A. Settipane et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2019)
Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach The Real-life Effectiveness of Omalizumab Therapy (REALITY) study
Harjinder Singh et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2019)
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
Claus Bachert et al.
LANCET (2019)
Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper
Franziska Roth-Walter et al.
ALLERGY (2019)
Sorting Out Nonadherence and Airway Inflammation in Treatment Escalation for Severe Asthma
Bruce G. Bender
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Perspectives in allergen immunotherapy: 2019 and beyond
Oliver Pfaar et al.
ALLERGY (2019)
Patients in the IDEAL cohort: A snapshot of severe asthma in France
C. Taille et al.
REVUE DES MALADIES RESPIRATOIRES (2019)
Immunologic mechanisms in asthma
Tadech Boonpiyathad et al.
SEMINARS IN IMMUNOLOGY (2019)
Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients
David Michalovich et al.
NATURE COMMUNICATIONS (2019)
Advancing the Care of Severe Asthma: Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Jonathan Corren et al.
AMERICAN JOURNAL OF MEDICINE (2019)
The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma
Giancarlo Marone et al.
FRONTIERS IN PHARMACOLOGY (2019)
Higher Binding Affinity and In Vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab
Mark Liddament et al.
ALLERGY ASTHMA & IMMUNOLOGY RESEARCH (2019)
Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
Osamu Matsuno et al.
RESPIRATORY MEDICINE CASE REPORTS (2019)
Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry
Giorgio Walter Canonica et al.
WORLD ALLERGY ORGANIZATION JOURNAL (2019)
Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study
Jean-Pierre Llanos et al.
JOURNAL OF ASTHMA AND ALLERGY (2019)
Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma
Maria Gabriella Matera et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)
Omalizumab could be effective in children with severe eosinophilic non-allergic asthma
M. Bourgoin-Heck et al.
PEDIATRIC ALLERGY AND IMMUNOLOGY (2018)
Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection
Molly M. Jeffery et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2018)
Efficacy of an Inhaled Interleukin-13 Antibody Fragment in a Model of Chronic Asthma
Daniel Lightwood et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab
Manali Mukherjee et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma
Bradley E. Chipps et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2018)
Nonadherence in the era of severe asthma biologics and thermoplasty
Joy Lee et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study
Marc Humbert et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Asthma across the lifespan: Time for a paradigm shift
Stanley J. Szefler
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab
Michelle A. Gill et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Sputum autoantibodies in patients with severe eosinophilic asthma
Manali Mukherjee et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Monitoring inflammatory heterogeneity with multiple biomarkers for multidimensional endotyping of asthma
Ioana Agache et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
The IL-33/ST2 axis is crucial in type 2 airway responses induced by Staphylococcus aureus-derived serine protease-like protein D
Andrea R. Teufelberger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Elevated Expression of IL-33 and TSLP in the Airways of Human Asthmatics In Vivo: A Potential Biomarker of Severe Refractory Disease
Yan Li et al.
JOURNAL OF IMMUNOLOGY (2018)
Epithelial damage and tissue γδ T cells promote a unique tumor-protective IgE response
Greg Crawford et al.
NATURE IMMUNOLOGY (2018)
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Klaus F. Rabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
M. Castro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Bronchial Thermoplasty in Severe Asthma: Best Practice Recommendations from an Expert Panel
Peter I. Bonta et al.
RESPIRATION (2018)
Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life
Dinh S. Bui et al.
LANCET RESPIRATORY MEDICINE (2018)
Tuning the Cytokine Responses: An Update on interleukin (IL)-4 and IL-13 Receptor Complexes
Ilkka S. Junttila
FRONTIERS IN IMMUNOLOGY (2018)
Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: Differences with Age
W. Gerald Teague et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2018)
IgE deficiency and prior diagnosis of malignancy Results of the 2005-2006 National Health and Nutrition Examination Survey
Denisa Ferastraoaru et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2018)
Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodies
Sathyadevi Venkataramani et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment
Stephanie Chen et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from Fc epsilon RI
Laura Maggi et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2018)
Bronchial Allergen Challenge of Patients with Atopic Asthma Triggers an Alarmin (IL-33, TSLP, and IL-25) Response in the Airways Epithelium and Submucosa
Wei Wang et al.
JOURNAL OF IMMUNOLOGY (2018)
A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma
Sanjeev Khindri et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
Current State and Future of Biologic Therapies in the Treatment of Asthma in Children
Elissa M. Abrams et al.
PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY (2018)
Recent developments and highlights in mechanisms of allergic diseases: Microbiome
Nonhlanhla Lunjani et al.
ALLERGY (2018)
Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
Rosalia Emma et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2018)
Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma
T. B. Casale et al.
ALLERGY (2018)
Predictors of clinical response to extrafine and non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma
Fajri Gafar et al.
RESPIRATORY RESEARCH (2018)
Comorbid treatable traits in difficult asthma: Current evidence and clinical evaluation
T. R. Tay et al.
ALLERGY (2018)
Care pathways for the selection of a biologic in severe asthma
Jean Bousquet et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Innate and adaptive type 2 immunity in lung allergic inflammation
Masato Kubo
IMMUNOLOGICAL REVIEWS (2017)
Role of IL-13 Genetic Variants in Signalling of Asthma
Madhavi Latha Alasandagutti et al.
INFLAMMATION (2017)
Management of severe asthma: targeting the airways, comorbidities and risk factors
Peter G. Gibson et al.
INTERNAL MEDICINE JOURNAL (2017)
Therapeutic efficacy of a co-blockade of IL-13 and IL-25 on airway inflammation and remodeling in a mouse model of asthma
Fang-Qi Zhang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2017)
dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies
Oscar Palomares et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Intraepithelial neutrophils in pediatric severe asthma are associated with better lung function
Cecilia K. Andersson et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Combined blockade of the IL-13 and IL-33 pathways leads to a greater inhibition of type 2 inflammation over inhibition of either pathway alone
Vladimir Ramirez-Carrozzi et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Anaphylaxis associated with omalizumab administration: Risk factors and patient characteristics
Phillip L. Lieberman et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial
Peter G. Gibson et al.
LANCET (2017)
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tezepelumab in Adults with Uncontrolled Asthma
Jonathan Corren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Childhood severe asthma: New insights on remodelling and biomarkers
Sejal Saglani
PAEDIATRIC RESPIRATORY REVIEWS (2017)
Local amplifiers of IL-4Rα-mediated macrophage activation promote repair in lung and liver
Carlos M. Minutti et al.
SCIENCE (2017)
Asthma Biomarkers: Do They Bring Precision Medicine Closer to the Clinic?
Ioana Agache et al.
ALLERGY ASTHMA & IMMUNOLOGY RESEARCH (2017)
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
Geoffrey L. Chupp et al.
LANCET RESPIRATORY MEDICINE (2017)
Altered Epithelial Gene Expression in Peripheral Airways of Severe Asthma
Akul Singhania et al.
PLOS ONE (2017)
Potential Role of the Lung Microbiome in Shaping Asthma Phenotypes
Kian Fan Chung
ANNALS OF THE AMERICAN THORACIC SOCIETY (2017)
The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis
L. E. Barry et al.
RESPIRATORY RESEARCH (2017)
Homeostatic Eosinophils: Characteristics and Functions
Thomas Marichal et al.
FRONTIERS IN MEDICINE (2017)
AllergoOncology - the impact of allergy in oncology: EAACI position paper
E. Jensen-Jarolim et al.
ALLERGY (2017)
Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
Manali Mukherjee et al.
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY (2017)
The Eosinophil in Infection
Karen A. Ravin et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2016)
Serum IL-5 and IL-13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asthmatics
I. Agache et al.
ALLERGY (2016)
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma Effects Across a Broad Range of Eosinophil Counts
Jonathan Corren et al.
CHEST (2016)
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels A Randomized Phase 3 Study
Leif Bjermer et al.
CHEST (2016)
Pathways through which asthma risk factors contribute to asthma severity in inner-city children
Andrew H. Liu et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia
Steven G. Smith et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Type 2 innate lymphoid cells in induced sputum from children with severe asthma
Prasad Nagakumar et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1
Timothy S. C. Hinks et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Distinguishing characteristics of difficult-to-control asthma in inner-city children and adolescents
Jacqueline A. Pongracic et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Lung-resident eosinophils represent a distinct regulatory eosinophil subset
Claire Mesnil et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Eugene R. Bleecker et al.
LANCET (2016)
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
Sally Wenzel et al.
LANCET (2016)
Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J. Mark FitzGerald et al.
LANCET (2016)
Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma
M. J. McGeachie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Qualitative effects of omalizumab on concomitant IgE-mediated disease in a severe asthmatic population: a real life observational study
R. P. Cusack et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2016)
Trained immunity: A program of innate immune memory in health and disease
Mihai G. Netea et al.
SCIENCE (2016)
Endotypes of allergic diseases and asthma: An important step in building blocks for the future of precision medicine
Ioana Agache et al.
ALLERGOLOGY INTERNATIONAL (2016)
Efficacy and Safety of Anti-Interleukin-5 Therapy in Patients with Asthma: A Systematic Review and Meta-Analysis
Fa-Ping Wang et al.
PLOS ONE (2016)
A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma
Jeffrey M. Harris et al.
RESPIRATORY RESEARCH (2016)
The Regulatory Function of Eosinophils
Ting Wen et al.
MICROBIOLOGY SPECTRUM (2016)
EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders
O. Boyman et al.
ALLERGY (2015)
Immunity to Helminths: Resistance, Regulation, and Susceptibility to Gastrointestinal Nematodes
Richard K. Grencis
ANNUAL REVIEW OF IMMUNOLOGY VOL 33 (2015)
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium
B. Rup et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2015)
The Complex Type 2 Endotype in Allergy and Asthma: From Laboratory to Bedside
Ioana Agache et al.
CURRENT ALLERGY AND ASTHMA REPORTS (2015)
IL-4 and IL-13 signaling in allergic airway disease
Naina Gour et al.
CYTOKINE (2015)
The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts
Louise Fleming et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations
Stephen J. Teach et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
The prevalence of severe refractory asthma
Pieter-Paul W. Hekking et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
Mario Castro et al.
LANCET RESPIRATORY MEDICINE (2015)
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Kian Fan Chung et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Elisabeth H. Bel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector G. Ortega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Exploring the Effects of Omalizumab in Allergic Asthma An Analysis of Biomarkers in the EXTRA Study
Nicola A. Hanania et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
From phenotypes to endotypes to asthma treatment
Ioana O. Agache
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Omalizumab Attenuates Airway Inflammation and Interleukin-5 Production by Mononuclear Cells in Patients with Severe Allergic Asthma
Yotaro Takaku et al.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2013)
Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia
Michel Laviolette et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects
William Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma
Sejal Saglani et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Effects of Omalizumab in Non-Atopic Asthma: Results from a Spanish Multicenter Registry
Luis Perez de Llano et al.
JOURNAL OF ASTHMA (2013)
Omalizumab: An update on efficacy and safety in moderate-to-severe allergic asthma
Bradley E. Chipps et al.
ALLERGY AND ASTHMA PROCEEDINGS (2012)
The expanding role(s) of eosinophils in health and disease
Elizabeth A. Jacobsen et al.
BLOOD (2012)
Development and validation of the Composite Asthma Severity Index-an outcome measure for use in children and adolescents
Jeremy J. Wildfire et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Pediatric severe asthma is characterized by eosinophilia and remodeling without TH2 cytokines
Cara J. Bossley et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
A Complement-IL-4 Regulatory Circuit Controls Liver Regeneration
Robert A. DeAngelis et al.
JOURNAL OF IMMUNOLOGY (2012)
An essential role for TH2-type responses in limiting acute tissue damage during experimental helminth infection
Fei Chen et al.
NATURE MEDICINE (2012)
Reslizumab for Poorly Controlled, Eosinophilic Asthma A Randomized, Placebo-controlled Study
Mario Castro et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications
Raed A. Dweik et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy A Randomized Trial
Nicola A. Hanania et al.
ANNALS OF INTERNAL MEDICINE (2011)
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables
Gordon Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
William W. Busse et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Wendy C. Moore et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
The effects of omalizumab on IgE-induced cytokine synthesis by asthmatic airway smooth muscle cells
Michael Roth et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2010)
MEDI-563, a humanized anti-IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
Roland Kolbeck et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Counterregulation between the FcεRI Pathway and Antiviral Responses in Human Plasmacytoid Dendritic Cells
Michelle A. Gill et al.
JOURNAL OF IMMUNOLOGY (2010)
Effect of omalizumab on peripheral blood eosinophilia in allergic asthma
M. Massanari et al.
RESPIRATORY MEDICINE (2010)
Omalizumab-induced decrease of FcεRI expression in patients with severe allergic asthma
Pascal Chanez et al.
RESPIRATORY MEDICINE (2010)
Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment
E. L. J. van Rensen et al.
ALLERGY (2009)
Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma
Bob Lanier et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease
Gary P. Anderson
LANCET (2008)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma
Oliver Noga et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2006)
IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma
M Kabesch et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2006)
Measurement properties and interpretation of three shortened versions of the asthma control questionnaire
EF Juniper et al.
RESPIRATORY MEDICINE (2005)
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment):: INNOVATE
M Humbert et al.
ALLERGY (2005)
Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma
R Djukanovic et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR
AM Vignola et al.
ALLERGY (2004)
Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma
JG Ayres et al.
ALLERGY (2004)
Omalizumab is effective in the long-term control of severe allergic asthma
BQ Lanier et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2003)
Interpreting thresholds for a clinically significant change in health status in asthma and COPD
PW Jones
EUROPEAN RESPIRATORY JOURNAL (2002)
Share Paper
